Attitudes surrounding implementation of the HPV vaccine for males among primary care providers serving large minority populations

Journal of Health Care for the Poor and Underserved

Volumn 24, Issue 2, 2013, Pages 768-776

  Aragones, Abraham ^a,b   Bruno, Denise ^b   Gany, Francesca ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Boys and men; HPV vaccine; Implementation; Primary care

Indexed keywords

EID: 84878451914     PISSN: 10492089     EISSN: 15486869     Source Type: Journal    
DOI: 10.1353/hpu.2013.0088     Document Type: Article

References (40)

1. National Cancer Institute. Surveillance epidemiology and end results. Washington, DC: National Cancer Institute, 2011.
2. Kahn JA, Lan D, Kahn RS. Sociodemographic factors associated with high-risk human papillomavirus infection. Obstet Gynecol. 2007 Jul;110(1):87-95.
3. Shikary T, Bernstein DI, Jin Y, et al. Epidemiology and risk factors for human papillomavirus infection in a diverse sample of low-income young women. J Clin Virol. 2009 Oct;46(2):107-11.
4. Hernandez BY, Barnholtz-Sloan J, German RR, et al. Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003. Cancer. 2008 Nov 15;113(10 Suppl):2883-91.
5. Joseph DA, Miller JW, Wu X, et al. Understanding the burden of human papillomavirusassociated anal cancers in the US. Cancer. 2008 Nov 15;113(10 Suppl):2892-900.
6. Centers for Disease Control and Prevention. Assessing the burden of hpv-associated cancers in the United States. Cancer. 2008;113(S10):2837-3057.
7. American Cancer Soceity. Cancer facts & figures 2011. Washington, DC: American Cancer Soceity, 2011.
8. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010 Oct 4;28(42):6858-67.
9. Barroso LF, Wilkin T. Human papillomavirus vaccination in males: the state of the science. Curr Infect Dis Rep. 2011 Apr;13(2):175-81.
10. Nelson B. A new front in the debate over HPV vaccines for boys: studies hint at broader benefits fron Gardasil. Cancer Cytopathol. 2010 Dec 25;118(6):413-4.
11. Centers for Disease Control and Prevention. 2009 Sexually transmitted diseases surveillance. Atlanta, GA: Centers for Disease Control and Prevention, 2010.
12. United States Food and Drug Administration. FDA approves new indication for gardasil to prevent genital warts in men and boys. Washington, DC: United States Food and Drug Administration, 2009.
13. United States Food and Drug Administration. Gardasil approved to prevent anal cancer. Washington, DC: United States Food and Drug Administration, 2011.
14. Romanowski B. Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines. Hum Vaccin. 2011 Feb 1;7(2).
15. Lu B, Kumar A, Castellsague X, et al. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis. 2011;11:13.
16. Pomfret TC, Gagnon JM, Gilchrist AT. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. J Clin Pharm Ther. 2011 Feb;36(1):1-9.
17. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009 Aug 19;302(7):750-7.
18. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011 Feb 3;364(5):401-11.
19. Garnock-Jones KP, Giuliano AR. Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the prevention of genital warts in males. Drugs. 2011 Mar 26;71(5):591-602.
20. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006 Nov;118(5):2135-45.
21. Laurence J. HPV-linked oral cancer: another argument for universal HPV vaccination of boys and girls. AIDS Read. 2008 Jul;18(7):345-6.
22. Kahn JA, Zimet GD, Bernstein DI, et al. Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health. 2005 Dec;37(6):502-10.
23. Riedesel JM, Rosenthal SL, Zimet GD, et al. Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol. 2005 Dec;18(6):391-8.
24. Zimet GD, Shew ML, Kahn JA. Appropriate use of cervical cancer vaccine. Annu Rev Med. 2008;59:223-36.
25. Tissot AM, Zimet GD, Rosenthal SL, et al. Effective strategies for HPV vaccine delivery: the views of pediatricians. J Adolesc Health. 2007 Aug;41(2):119-25.
26. Noakes K, Yarwood J, Salisbury D. Parental response to the introduction of a vaccine against human papilloma virus. Hum Vaccin. 2006 Nov-Dec;2(6):243-8.
27. Dempsey AF, Butchart A, Singer D, et al. Factors associated with parental intentions for male human papillomavirus vaccination: results of a national survey. Sex Transm Dis. 2011 Feb 17;23(2):128-41.
28. Das A, Madhwapathi V, Davies P, et al. Knowledge and acceptability of the HPV vaccine by school children and their parents in Birmingham. Vaccine. 2010 Feb 10;28(6):1440-6.
29. Starfield B, Shi L, Macinko J. Contribution of primary care to health systems and health. Milbank Q. 2005;83(3):457-502.
30. Macinko J, Starfield B, Shi L. Quantifying the health benefits of primary care physician supply in the United States. Int J Health Serv. 2007;37(1):111-26.
31. Grumbach K, Bodenheimer T. A primary care home for Americans: putting the house in order. JAMA. 2002 Aug 21;288(7):889-93.
32. Chang CH, Stukel TA, Flood AB, et al. Primary care physician workforce and Medicare beneficiaries' health outcomes. JAMA. 2011 May 25;305(20):2096-104.
33. United Sates Census Bureau. American community survey. Washington, DC: United Sates Census Bureau, 2011.
34. Ajzen I. The theory of planned behavior. Organizational Behavior and Human Decision Processes. 1991;50:179-211
35. Delnevo CD, Abatemarco DJ, Steinberg MB. Physician response rates to a mail survey by specialty and timing of incentive. Am J Prev Med. 2004 Apr;26(3):234-6.
36. IBM Corp. IBM SPSS statistics for windows, version 19.0. Armonk, NY: IBM Corp, 2010.
37. United Sates Census Bureau. New York city community health survey. Washington, DC: United Sates Census Bureau, 2011.
38. Keating KM, Brewer NT, Gottlieb SL, et al. Potential barriers to HPV vaccine provision among medical practices in an area with high rates of cervical cancer. J Adolesc Health. 2008 Oct;43(4 Suppl):S61-7.
39. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer. 2007 Nov 5;97(9):1322-8.
40. Centers for Disease Control and Prevention. Genital HPV infection fact sheet. 2009. Atlanta, GA: Centers for Disease Control and Prevention, 2011.